The multicenter, randomized phase III ADMIRAL trial (NCT02421939) confirmed that gilteritinib significantly improves OS and CR rates compared to chemotherapy, with fewer adverse events and a comparable safety profile, in R/R AML patients with FLT3 mutations, leading its FDA approval for this indication [135–137]. Here, FLT3 is linked to acute myeloid leukemia.